Relay Therapeutics Quarterly Cash Flow Statement
NASDAQ: RLAYHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
17.88+0.47 (+2.70%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Relay Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Relay Therapeutics generated -$54.1 million of operating cash flow. That left free cash flow of -$54.1 million, a free-cash-flow margin of -15459.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Relay Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -83.71M | -73.29M | -54.89M | -74.15M | -70.38M | -77.06M | -76.00M | -88.11M | -92.21M | -81.39M | -83.50M | -65.73M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 360.00K | 504.00K | 599.00K | 748.00K | 1.00M | 1.21M | 1.33M | 1.37M | 1.37M | 1.40M | 1.38M | 1.36M |
| Stock-Based Compensation | 9.18M | 10.54M | 13.07M | 15.53M | 14.50M | 19.32M | 17.64M | 22.48M | 26.83M | 27.19M | 19.27M | 21.84M |
| Change in Working Capital | 20.93M | 4.05M | -7.15M | -38.00K | -2.03M | -11.43M | -6.66M | -3.71M | 2.31M | 560.00K | -21.88M | -20.86M |
| Operating Cash Flow | -54.11M | -51.11M | -44.87M | -62.12M | -55.26M | -73.21M | -57.87M | -75.08M | -65.83M | -50.32M | -89.19M | -75.40M |
| Capital Expenditures | — | — | -1.00K | 1.00K | -26.00K | -384.00K | 0 | -227.00K | -11.00K | -1.78M | -118.00K | -590.00K |
| Investing Cash Flow | -353.03M | 32.90M | 35.46M | 39.73M | 75.15M | 42.47M | 29.00M | -126.16M | 45.55M | 10.53M | 59.68M | 71.36M |
| Financing Cash Flow | 323.74M | 138.78M | 934.00K | 17.00K | — | — | 800.00K | 218.89M | 1.54M | 48.92M | 21.92M | 9.46M |
| Net Change in Cash | -83.40M | 120.57M | -8.47M | -22.38M | 20.54M | -30.75M | -28.07M | 17.64M | -18.74M | 9.13M | -7.59M | 5.43M |
| Free Cash Flow | -54.11M | -51.11M | -44.87M | -62.12M | -55.29M | -73.59M | -57.87M | -75.31M | -65.84M | -52.10M | -89.31M | -75.99M |
This table shows 12 quarterly periods of Relay Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RLAY's reporting calendar. What is a cash flow statement?